Dementia Cases in the U.S. Will Surge in the Coming Decades, Researchers Say
By 2060, new dementia cases per year could double to one million because of the growing population of older Americans, a ...
Dementia risk is rising in an aging US population. Cases are projected to double by 2060
New research suggests that the risk for developing dementia is significantly higher than previously estimated, and the burden ...
The Amazing Times on MSN3d
Five Common Medications That May Increase Your Risk of Dementia
Dementia, a progressive disorder that impacts memory and independence, affects millions globally. While many are aware of ...
Your Good Health: Long-term use of high-dose gabapentin worries patient
The evidence of gabapentin and dementia is mixed, with two studies looking at hundreds of thousands of people and coming to ...
Medical News Today4d
Common sleep medication may prevent brain from clearing 'waste'
In a mouse study, researchers found that zolpidem (Ambien), a common sleep aid, could prevent the brain from effectively ...
New criteria developed for appropriate use of cognitive impairment imaging tools
Appropriate use criteria (AUC) for the use of amyloid and tau positron emission tomography (PET) have been issued by the ...
Blackpool Gazette1d
Blackpool doctor who punched a dementia patient in the head is struck off medical register
A doctor who punched a dementia patient in the head and pushed his head into a pillow, has been erased from the medical ...
Benzinga.com4d
FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi
Leqembi's subcutaneous dosing allows Alzheimer's patients to administer weekly treatment at home in 15 seconds ... s disease ...
Monthly Prescribing Reference1d
Lecanemab SC Formulation Under Review for Early Alzheimer Disease
The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...
FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi ...
Dementia risk may be twice as high as Americans live longer, study finds
The risk of developing dementia may be much higher than previously thought, a study published Monday in the journal Nature ...